Idiopathic pulmonary fibrosis (IPF) is a debilitating, progressive, and incurable lung disease. Until recently, no medications were known to slow disease progression. In just the past 5 years, two new FDA-approved therapies have been demonstrated to slow progression of IPF as measured by forced vital capacity.
Fortunately, improvement in long-term outcomes can now be achieved by early and accurate diagnosis followed by appropriate treatment. In this ReCAP, Dr Fernando Martinez of Weill Cornell Medicine discusses the diagnosis and treatment options now available for IPF.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Idiopathic Pulmonary Fibrosis - Medscape - Jan 24, 2020.
Comments